Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: crysball who wrote (290)	12/7/1998 2:21:00 PM
From: Dr. John M. de Castro	Read Replies (2) of 1386

One possibility is Elan. It may be both a category 2 and 3 company. They announced a massive financing to fund acquisitions particularly within their central nervous system focus. biz.yahoo.com In addition, they just terminated a TBI trial with Neurex's SNX-111. Although that might make them gun shy, it also means that they have a consortium of trial sites and the in house expertise to field a large Phase III trial. The other side of the argument is that I've heard that only American companies are serious candidates for HU-211 partnering. Elan is Irish. This is completely hearsay and I have no direct evidence. So, I still regard ELN as a viable candidate. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next